|
|
|
|
AldurazymeWebbolt Business News (subscription), Sales of Aldurazyme(R) (laronidase) enzyme replacement therapy for MPS I were $21 million in the fourth quarter, up 31 percent compared with $16 million in the ... Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue Jan 10, 2006 Oxfordshire Bioscience Network (press release), Sales of Aldurazyme® (laronidase) enzyme replacement therapy for MPS I were $21 million in the fourth quarter, up 31 percent compared with $16 million in the ... Schaeffer's Top and Bottom Ranked Stocks (BMRN, ELNK, LGF) Jan 12, 2006 Schaeffers Research, The company's orphaned medications are Aldurazyme, which was the first drug approved by the US and European Union to treat mucopolysaccharidosis I, or Hurler ... BioMarin Establishes Commercial Operations in Europe Jan 10, 2006 PR Newswire (press release), ...include Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme(R) (laronidase ... BioMarin Establishes Commercial Operations in Europe Jan 10, 2006 Yahoo! News (press release) Naglazyme(TM) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, Aldurazyme® (laronidase) for ... Manager favors Foundry Networks, BioMarin Dec 29, 2005 MSN Money Its Aldurazyme (developed through a joint venture with Genzyme), is the first drug approved in the United States and Europe to specifically treat the life ... Rare-disease sufferers want drugs fast-tracked Dec 29, 2005 The Japan Times, Genzyme has applied to the ministry for approval of the drug, marketed under the name aldurazyme, and if all goes well it probably will be on the market here ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |